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Breast tumours responding to chemotherapy exhibit decreased [18F]ﬂuoro-2-deoxy-D-glucose ([18F]FDG) incorporation.
Underlying mechanisms of these changes is poorly understood. Here, in MCF-7 cells, responding to chemotherapy drugs
commonly utilised in the treatment of breast cancer, [18F]FDG incorporation and several pivotal factors associated with [18F]FDG
incorporation investigated. Methods. IC50 and subclinical doxorubicin, docetaxel, and tamoxifen doses determined using MTT
assay. [18F]FDG incorporation by cells treated with IC50 drug doses for 48 hours and 72 hours were determined and FDG
dephosphorylation estimated by measuring loss of 18F from [18F]FDG-preincubated cells (pulse-chase). Glucose transport
determined by measuring initial uptake rate of non-metabolised glucose analogue omethylglucose; hexokinase activity and
ATP content measured in cell homogenates; Cell cycle distribution determined using ﬂow cytometry of propidium iodide
stained nuclei. Results.[ 18F]FDG incorporation and ATP content decreased in cells after 72 hours treatment with IC50 doses
of tamoxifen, doxorubicin, and docetaxel compared with untreated controls. Decreased glucose transport and/or hexokinase
activity accompanied decreased [18F]FDG incorporation by MCF-7 cells treated with tamoxifen or doxorubicin but not docetaxel.
Conclusions.T u m o u rc e l l[ 18F]FDG incorporation along with ATP content decreased by treatment with tamoxifen, doxorubicin
and docetaxel paralleling clinical observations for solid tumours. Eﬀect of each treatment on glucose transport and hexokinase
activity was chemotherapy-drug dependent.
1.Introduction
Breast cancer is the most common form of neoplasia in
women accounting for almost a third of all new cases
of women’s cancer [1]. Locally advanced breast cancer is
currently treated using neoadjuvant therapy consisting of
anthracyclines such as doxorubicin or taxanes [2, 3] includ-
ing docetaxel. Tamoxifen, an antioestrogen, is commonly
used for the adjuvant treatment of postmenopausal women
presenting with early breast cancer.
Both short-term and long-term toxicities are associated
with the use of [2] adjuvant chemotherapy. Tamoxifen has
side eﬀects including hot ﬂushes and vaginal discharges and
other more serious side eﬀects including thromboembolic
disorders [4], and there are a number of novel aromatase
inhibitors with more favourable tolerability [5]. Aromatase
inhibitors act by inhibiting the synthesis of oestrogen from
adrenal androgens in peripheral tissue thus reducing its level
in the circulation of postmenopausal women in whom this is
the major source of oestrogen.2 International Journal of Molecular Imaging
In view of the cytotoxic aﬀects of adjuvant chemotherapy
and tamoxifen treatment, early response indicators have
been sought including the use of [18F]Fluoro-2-deoxy-D-
glucose positron emission tomography ([18F]FDG-PET) [6–
8]. Serial PET scanning of patients with breast cancer has
shown that tumour response to chemotherapy is generally
accompanied by decreased incorporation of [18F]FDG [6–
8]. However, tumours of patients treated with tamoxifen
have been shown to exhibit increased [18F]FDG uptake
[9].
FDG enters cells by passive and facilitated diﬀusion.
The latter is carried out by a family of glucose transporter
molecules called gluts which exhibit altered expression in
tumour cells compared with normal tissue [10]. On entering
thecell,[18F]FDGisrapidlyphosphorylatedbyhexokinaseto
[18F]FDG-phosphate. Due to the near absence from tumour
cells of glucose-6-phosphatase [11, 12]a n d[ 18F]FDG-
phosphate being a poor substrate for the next enzyme in
the glycolytic pathway, FDG becomes trapped in the cell as
[18F]FDG-phosphate. The extent to which modulation of
these steps by chemotherapy contributes to therapy-induced
changes in [18F]FDGincorporationatthetumourcelllevelis
poorly understood but would be useful in the interpretation
of clinical studies. One previous study of [18F]FDG uptake
by MCF7 cells examined the eﬀect of a 24-hour exposure
of 1µmol/L doxorubicin on the gene and protein expression
of hexokinase II and glut1 [13]. Their results showed that
whilst glut1 expression was increased during exposure, there
was no change in glut1 expression at the protein level. HKII
expression was found to be diminished at both the mRNA
and protein levels. Both glucose transporters [10, 14]a n d
hexokinases [15] are highly regulated, so protein expression
may not necessarily reﬂect functional activity
In this study, we have determined whether or not treat-
mentwithIC50 dosesoftamoxifen,doxorubicin,ordocetaxel
modulate [18F]FDG incorporation at the tumour cell level
and how these changes relate to HK activity and glucose
transport, at the functional level, dephosphorylation/eﬄux.
Decreased ATP levels are associated with drug response [16–
18] and are likely to inﬂuence phosphorylation of [18F]FDG
so we also determined ATP content during tumour cell
response. Some regions of tumours are poorly perfused so
drug levels that tumour cells are exposed to in those regions
may be quite low. In view of this, we have also measured
[18F]FDG uptake by cells treated with subclinical doses of
chemotherapy agents to determine if changes in [18F]FDG
uptake occur in the absence of appreciable tumour growth
inhibition.
2.MaterialsandMethods
All chemicals were obtained from Sigma-Aldrich (Poole UK)
unless otherwise stated.
2.1. Cells and Treatments. MCF-7 cells, an oestrogen-
receptor positive breast cancer line, were cultured in DMEM
(Invitrogen, Paisley, United Kingdom), and supplemented
with 10% foetal bovine serum (FBS), 50 units/ml penicillin,
and 50µg/ml streptomycin.
2.2. Cell Viability. C e l l sw e r eg r o w nt oc o n ﬂ u e n c yi n7 5c m 2
ﬂasks and after trypsinising and addition of medium the
cell number was corrected to 15,000 per ml. One hundred
microlitres of cell suspension was seeded into 96 well
plates and the plates incubated at 37◦C overnight. Media
(100µl), supplemented with varying concentrations of the
chemotherapeutic agents to produce ﬁnal concentrations
within the following ranges: tamoxifen (0.1–20µM); dox-
orubicin(0.001–0.1µM);docetaxel(0.00001–0.001µM),was
then added to each well (200µl/well in total) and the plate
returned to the incubator. A background of 200µl of media
and a control of 200µl of media and cells were also set up.
A f t e re i t h e r4 8o r7 2h o u r s ,5 0 µlo fM T Tw a sa d d e dt o
each of the wells and incubated for 3-4 hours. The media
was then aspirated using a syringe, and 200µlo fD M S O
(dimethylsulfoxide) was then added to each well. Each plate
was then placed in a scanning multiwell spectrophotometer
(Dynatech MR5000, Dynatech Labarotaries Inc., Chantilly,
VA, USA) and agitated for 30 seconds prior to measuring
spectrophotometricabsorbanceat570nm(testﬁlter570nm,
reference ﬁlter 690nm). The plates were analysed using
Biolinx 2.0 software (Biolinx 2.0, Dynatech Labarotaries
Inc.).
2.3. [18F]FDG Incorporation. Cells were seeded in 25cm2
tissue culture ﬂasks and 3 days later treated with IC50 and
subclinical doses of tamoxifen (10µM and 0.05µM, resp.),
doxorubicin (0.1µM and 0.0025µM, resp.), and docetaxel
(0.5nM and 0.001nM, resp.). At the time of [18F]FDG
uptake determination, medium was replaced with 1ml
of fresh medium (glucose concentration 1mg/ml (5mM)
whichisthelevelofglucoseintheplasmaofnormalsubjects)
containing37KBq[18F]FDGandincubatedfor20minutesat
37◦C. Cells were then washed 5 times with 5ml of ice cold
PBS and detached by addition of trypsin. After addition of
media to neutralise the trypsin, 0.2ml was prepared for cell
cycle analysis, and 0.8ml of cell suspension was transferred
into Eppendorf tubes for determination of [18F]FDG uptake
in a well counter. The cells were then centrifuged, washed
with 1ml of PBS, the pellet was dissolved in 0.1ml NaOH
(1M) and after neutralising with 0.1ml HCl, protein content
was determined.
2.4. [18F] FDG Release. [18F]FDG cellular release was deter-
mined by the modiﬁed method of Carac´ o et al. [12]. Cells
treated and incubated with [18F]FDG as described above
were washed 5x with 5ml of ice-cold PBS. Cells were then
incubated in 1ml of fresh media for 5 minutes to allow eﬄux
of non-phosphorylated [18F]FDG. Cells were then incubated
in 1ml of fresh media for 20 minutes. After removal of the
medium and detachment of the cells, activity in the media
and cells was determined. Activity eﬄuxed was expressed
relative to incorporated activity.
2.5. Glucose Transport. Glucose transport rate was deter-
mined by incubating cells with [3H] o-methyl-glucose ([3H]
OMG) and the amount taken up during the initial linear
phase of uptake considered to be a measure of glucose
transport, which was determined by [19].International Journal of Molecular Imaging 3
Flasks of cells were seeded as for FDG uptake and
treated with IC50 doses of tamoxifen (10µM), doxorubicin
(0.1µM), and docetaxel (0.5nM) for 72 hours. The media
was then discarded and replaced with fresh media (glucose
concentration1mg/ml)containing37KBqof[3H]OMGand
0 . 1m M“ c o l d ”O M Gf o r1 0s e c o n d s( [ 3H] OMG uptake by
MCF-7 cells is linear for at least 30 seconds [11]) at 37◦C.
The incubation was ended by rapid addition of 5ml of ice-
coldPBScontainingtheglucosetransportinhibitorphloretin
(0.1mM) followed by 3 further rapid washes. Cells were then
trypsinised, half of them were added to 5ml of Optima Gold
scintillationﬂuid(PerkinElmer,UnitedKingdom),and[3H]
OMG uptake was determined in a scintillation counter. The
remaining cells were prepared for protein assay.
To determine nonfacilitated transport of [3H] OMG
further, ﬂasks of cells were coincubated with [3H] OMG and
250mM OMG to block facilitated uptake.
2.6. Hexokinase Activity. The preparation of cellular
homogenates and the hexokinase assay was based on that of
Miccoli et al. [20]. Cells were seeded in 75cm2 ﬂasks and
after 3 days treated with IC50 doses of tamoxifen (10µM),
doxorubicin (0.1µM), and docetaxel (0.5nM) for 72 hours
then harvested by trypsinisation. After addition of medium,
they were collected into Eppendorf tubes, washed with
PBS, and centrifuged at 400g for 1 minute, and the pellet
was resuspended in 0.2ml homogenisation buﬀer (10mM
Tris/HCl, pH7.7 0.25mM sucrose, 0.5mM dithiothreitol,
1mM aminohexanoic acid, and 1mM PMSF). They were
then transferred to a 1ml glass dounce homogeniser and
homogenised by 10 strokes at 4◦C. The homogenised cells
were transferred to an Eppendorf tube and centrifuged for
10 minutes at 1000g to remove cell debris. The supernatant
was transferred to a new Eppendorf tube, and the pellet
was washed with 0.2ml of homogenisation buﬀer, and the
supernatant pooled. Protein content of the homogenate was
determined on a 20µls a m p l e .
Hexokinase enzyme protein level was determined by the
addition of 100µl of homogenate to 0.9ml of assay medium
consisting of 100mM Tris/HCl (pH 8.0), 10mM glucose,
0.4mM NADP+,1 0m MM g C l 2, 5mM ATP, and 0.15 unit
of glucose-6-phosphate dehydrogenase in a cuvette at 37◦C.
The reaction was followed by monitoring the change in
absorbance at 340nm due to the formation of NADPH.
2.7. ATP Content. ATP content of treated and untreated
cells was determined using a commercial kit (Sigma-Aldrich,
Poole, UK) following the manufacturer’s instructions.
2.8. Flow Cytometry. Flasks of cells were seeded as for FDG
uptake and treated with IC50 doses of tamoxifen (10µM),
doxorubicin (0.1µM), and docetaxel (0.5nM) for 72 hours.
Cells were harvested by tryspinization and collected into
Eppendorf tubes. They were then centrifuged at 1000g for
5 minutes and after removing the supernatant the pellet was
washed with PBS and the pellet ﬁxed by the slow addition
of 1ml of ice-cold 70% ethanol and left at −20
◦Cf o ra t
least 24 hours. The ﬁxed cells were then washed with PBS
containing 1% serum then resuspended in staining buﬀer
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Figure 1: Cell viability determined by the MTT assay. Eﬀect of
tamoxifen (a), doxorubicin (b), or docetaxel (c) for 48 hours (black
diamonds) and 72 hours (white squares) on MCF-7 tumour cell
growth determined using the MTT assay and expressed relative to
untreated cells. Each determination was carried out 3 times.
at 4◦C for at least 20 minutes prior to analysis. The cell
number was then determined using a haemocytometer and
the cell concentration was adjusted to 1 × 106 cells in a
volume of 0.5ml of propidium iodide (PI)/RNase staining
buﬀer and the suspension was incubated for 15 minutes
at room temperature. The stained cells were kept at 4◦C
and protected from light. Flow cytometry was performed
using 488nm lazer light on a FACSCalibur ﬂow cytometer
(Becton Dickinson) and ﬂowjo software (Treestar) with
doublet discrimination.
2.9. Statistics and Replicates. Signiﬁcant diﬀerences between
means were established using the Student t-test. The t value
and corresponding level of signiﬁcance is shown in brackets,
for example, (t = 3,P<. 05); if the diﬀerence between the
means is not signiﬁcantly diﬀerent, this is written as (t = 3,
ns).
3. Results
3.1. Cell Viability. Figure 1 shows the decrease in cell
number, determined using the MTT assay after treatment
of MCF7 cells for 48 and 72-hour. Drug concentrations
that produced about a 50% decrease in cell number after4 International Journal of Molecular Imaging
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Figure 2: Cell cycle distributions determined on control and treated MCF-7 cells. Control (a) and MCF-7 cells treated with Tamoxifen (b),
Doxorubicin (c), and docetaxel (d).
72 hours treatment (IC50) were tamoxifen 10µM; Doxoru-
bicin 100nM; docetaxel 0.5nM.
3.2. Flow Cytometry. Cell cycle distributions for control and
treatedMCF7cellsareshowninFigure 2.T reatmentofMCF-
7 cells with tamoxifen was found to result in a decrease
in S-phase cells compared with controls (t = 2.94,P<. 05)
whereas treatment of cells with doxorubicin resulted in a
buildup of cells in G2. A subG1, indicative of an apoptotic
population, was not evident in adherent cells after either
tamoxifen or doxorubicin. However, a subG1 peak was
associated with about 25% of cells treated with docetaxel.
DNA analysis was also carried out on MCF-7 cells after 48
hourstreatment(resultsnotshown)andshowedverysimilar
cell cycle distributions to that of MCF-7 cells treated for 72
hours.
3.3. [18F]FDG Incorporation. [18F]FDG uptake after treat-
ment of MCF-7 cells with tamoxifen, doxorubicin, or doc-
etaxel for 48 hours and 72 hours followed by incubation withInternational Journal of Molecular Imaging 5
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Figure 3: FDG incorporation by control and MCF-7 cells treated
for 48 hours (black, n = 5 replicates) or 72 hours (white n = 10
or more replicates) with tamoxifen, doxorubicin, or docetaxel as a
percentage of incorporation by untreated cells.
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Figure 4: Glucose transport by control and treated MCF-7 cells
determinedbyuptakeofOMGduringﬁrst10secondsofincubation
of cells with 0.1mM OMG (black) or 250mM OMG (white).
[18F]FDG for 20min is shown in Figure 3. Compared with
controlcellstreatmentwithtamoxifen(t = 1.22,ns)doxoru-
bicin (t = 0.3, ns), or docetaxel (t = 2.13, ns) for 48 hours
did not result in a signiﬁcant change in FDG incorporation.
Compared with control cells, [18F]FDG incorporation was
signiﬁcantly decreased by cells treated for 72 hours with
tamoxifen (t = 10,P<. 001) by 45%, doxorubicin (t =
6.4,P<. 001) by 24%, and docetaxel (t = 9.6,P<. 001) by
29%.
The rate of eﬄux of 18F from cells incubated with
[18F]FDG for 20 minutes was determined (results not
shown). Compared with untreated cells, there was no signif-
icant diﬀerence in the rate of eﬄux of [18F]FDG from cells
treated with tamoxifen or docetaxel. However, cells treated
with doxorubicin exhibited a signiﬁcantly (t = 9.35,P<
.005) lower rate of 18Fe ﬄux compared with untreated
cells.
Treating MCF-7 cells with subclinical amounts of tamox-
ifen or doxorubicin for 72 hours did not result in signiﬁcant
changes in [18F]FDG uptake. However, treatment with a
subclinicaldoseofdocetaxelcausedasigniﬁcant(t = 2.9,P<
.01) decrease in [18F]FDG uptake although this change was
less than 10% (results not shown).
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Figure 5: Hexokinase activity in MCF-7 cells treated for 72 hours
with tamoxifen (n = 6), doxorubicin (n = 6), or docetaxel (n = 5)
as a percentage of activity in untreated cells (n = 9).
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Figure 6: ATP content of MCF-7 cells treated for 72 hours with
tamoxifen (n = 6), doxorubicin (n = 6), or docetaxel (n = 6) or
untreated (n = 6).
3.4. Glucose Transport. Figure 4 shows the uptake of [3H]
OMG by MCF-7 cells incubated with [3H] OMG for 10 sec-
onds and either 0.1mM OMG or a blocking concentration
of 250mM OMG. Transport of [3H] OMG was signiﬁcantly
reduced by the treatment of cells with doxorubicin (t =
3.01,P<. 01) and tamoxifen (t = 4,P<. 01) but not by
docetaxel (t = 0.05, ns). The presence of 250mM OMG
reduced uptake of [3H] OMG, and there was no signiﬁcant
diﬀerence in uptake by control cells compared with uptake
by tamoxifen-(t = 1.6, ns), doxorubicin (t = 0.35, ns)
and docetaxel (t = 1.6, ns) suggesting that the rate of
nonfacilitated uptake was the same by control and treated
cells.
3.5. Hexokinase Activity. Figure 5 shows hexokinase activity
in MCF-7 control and in cells treated with tamoxifen, dox-
orubicin, and docetaxel. Tamoxifen treatment signiﬁcantly
(t = 3.06,P<. 01) decreased HK activity whereas the
treatment with doxorubicin actually increased HK activity
(t = 4.37,P<. 01). Treatment with docetaxel (t = 0.56, ns)
did not signiﬁcantly aﬀect HK activity.
3.6. ATP Content. Figure 6 shows ATP content in untreated
and treated MCF-7 cells. Compared with control cells, ATP
content was signiﬁcantly decreased after treatment with6 International Journal of Molecular Imaging
tamoxifen (t = 3.7,P<. 01),doxorubicin(t = 2.45,P<. 02),
and docetaxel (t = 3.33,P<. 003).
4. Discussion
The ﬁndings of clinical [18F]FDG-PET studies have shown
that the incorporation of [18F]FDG by breast tumours
responding to adjuvant therapy is decreased compared with
pretreatment uptake [6–8] .H e r e ,w eh a v ed e t e r m i n e di f
changes in [18F]FDG uptake can be seen at the tumour
cell level and have shown that [18F]FDG incorporation by
MCF-7 cells was decreased after 72 hours of treatment
with tamoxifen, doxorubicin, and docetaxel. The extent to
whichFDG incorporation is decreasedvaried with treatment
type with tamoxifen inducing almost a 45% decrease in
uptake whereas doxorubicin decreased incorporation by
less than 25%. Such diﬀerential eﬀect between treatments
suggests that the sensitivity of changes in FDG incorporation
to detect tumour response may be chemotherapy agent
dependent.
Clinical studies of tamoxifen-treated breast tumours
show an increase in metabolism at 1–2 weeks after starting
treatment [9]. In this study, we found that treatment of
both MCF-7 breast tumour cells for 72 hours with the
IC50 dose of tamoxifen reduced [18F]FDG uptake. Clinical
studies reporting a “metabolic ﬂare” were performed shortly
after patients started on a course of tamoxifen before blood
concentrations would have achieved a growth-inhibitory
level, and it has been shown that tamoxifen can be growth
stimulating at low concentrations [9] perhaps accounting for
the increase in [18F]FDG uptake observed after beginning
tamoxifen treatment. Our ﬁndings suggest that when the
tumouris regressing inresponse totherapy[18F]FDGuptake
per tumour cell will be diminished.
[18F]FDG incorporation has been shown to be a measure
of cellular glucose utilization by brain tissue [21]. Studies
[22] using 13C-NMR spectroscopy to probe 13C-glucose
utilization have demonstrated that, compared to pretreat-
ment, tamoxifen-treated MCF-7 cells exhibit a 50% decrease
in glucose ﬂux comparable to the decrease in [18F]FDG
incorporation by MCF-7 cells in response to tamoxifen
treatment reported in the present paper suggesting that
[18F]FDG is measuring changes in glucose utilization in
response to tamoxifen treatment.
We have previously shown that MCF-7 cells express
glucose transporters 1, 8, and 10 and that HK I is the
principal HK in this cell line [11]. In the present study, HK
activity was decreased in MCF-7 cells after treatment with
tamoxifen whilst HK activity was enhanced in doxorubicin-
treated MCF7 cells. However, the decrease in [18F]FDG
incorporation by MCF-7 cells treated with tamoxifen or with
doxorubicin paralleled decreased levels of glucose transport
observed in this tumour line. Previously, it has been shown
thathypoxia-inducedincreasesin[18F]FDGuptakebyMCF-
7cellshasbeenshowntobeassociatedwithincreasedglucose
transporter activity [23].
Decreased [18F]FDG incorporation by MCF-7 cells
treated with docetaxel did not correspond with changes
in glucose transport or HK activity. To determine whether
or not treatment of MCF-7 cells increased the rate of
dephosphorylation of [18F]FDG-phosphate, the rate of
[18F]FDG eﬄux was determined in cells labelled with
[18F]FDG. During the initial 5-minute incubation in fresh
medium of cells preincubated with [18F]FDG about 10%
of activity was lost from the cells (results not shown)
consistent with our previous ﬁnding that 90% of [18F]FDG
in MCF-7 cells is in the phosphorylated form [11]a n d
in agreement with other workers [12]. During the sub-
sequent 20-minute incubation, eﬄux was found to be
appreciable despite the absence of expression of glucose-
6-phosphatase from MCF-7 cells [11]. Dephosphorylation
of [18F]FDG phosphate by cells not expressing glucose-
6-phospatase has been described previously [12, 24] sug-
gesting the presence of glucose-6-phosphatase-independent
mechanisms for [18F]FDG-phosphate dephosphorylation.
T h er a t eo fe ﬄux of [18F]FDG from cells preincubated
with [18F]FDG was modulated only in cells treated with
doxorubicin. Thus, changes in dephosphorylation rate in
docetaxel-treated cells could not account for the decrease
in [18F]FDG incorporation compared with untreated
cells.
Compared with untreated cells, ATP content was found
to be decreased in MCF-7 cells treated for 72 hours with each
drug. Decreased ATP content in toxin-treated cells including
ones exhibiting apoptosis has also been reported previously
[16–18]. In the absence of changes in other factors, the
decrease in [18F]FDG incorporation by MCF-7 cells treated
with docetaxel is likely to reﬂect decreased ATP content.
Changes in cell cycle distribution of MCF-7 cells induced
by tamoxifen or doxorubicin do not appear to be associ-
ated with the decrease in [18F]FDG uptake since although
[18F]FDG accumulation was decreased by these agents,
tamoxifen caused only minor changes in the cell cycle
distribution with a small increase in G1 population whilst
doxorubicin treatment caused an accumulation of cells in
G2. This is in agreement with a previous paper [11], in
which it was reported that treatment of MCF-7 cells with
colchicine, which induces a buildup of cells in G2, was not
associatedwithachangein[18F]FDGuptake.Afurtherpoint
isthatchangesinCellcycledistributionafter48hoursofeach
treatmentaresimilartothoseseenafter72hours.Incontrast,
the decreased FDG incorporation seen after 72 hours is not
evident after 48 hours.
Docetaxel treatment induced apoptosis in adherent
MCF-7 cells, however, the extent of decrease in [18F]FDG
incorporation was similar to that of cells responding to treat-
ment with doxorubicin and tamoxifen. Decreased [18F]FDG
uptake by apoptotic tumour cell populations has recently
been reported by Takei et al. [25], who showed that the
decreased uptake of [18F]FDG in tumours derived from
allogenic hepatoma cells grown in rats responding to treat-
ment with gemcitabine and cyclophosphamide correlated
with an enhanced apoptotic reaction. Takei et al. [25]
did not observe any change in glut1 protein levels after
treatment with either gemcitabine or cyclophosphamide.
Similarly, we did not observe changes in glucose transport
in MCF-7 cells treated with docetaxel. Increases in [18F]FDG
incorporation could be expected to occur at early timeInternational Journal of Molecular Imaging 7
points during therapy. Changes in mitochondrial mem-
brane potential are associated with apoptosis, and we have
previously shown that perturbation of the mitochondrial
membrane can induce increases in [18F]FDG incorporation
[26]. The diﬀerence in the uptake of [18F]FDG by cells
treated for 48 hours (no change from controls) and 72 hours
(decreased compared with controls) with chemotherapy
agents illustrates the importance of the correct timing
of posttreatment PET scans when using PET to measure
response.
As well as treating MCF-7 cells with IC50 drug con-
centrations, cells were also treated with subclinical doses of
drugs, that is, a concentration that produced less than a 5%
reduction in tumour cell number at 72 hours. We found
no signiﬁcant change in [18F]FDG uptake after treating cells
with such doses of doxorubicin or tamoxifen, but treatment
of MCF-7 cells with a subclinical dose of docetaxel resulted
in a small but signiﬁcant decrease in [18F]FDG uptake. This
suggests that even very low levels of clinical response to some
chemotherapy agents may be accompanied by changes in
[18F]FDG uptake.
I nv i v o ,o t h e rf a c t o r sw o u l db ee x p e c t e dt oc o n t r i b u t e
to [18F]FDG incorporation including [18F]FDG delivery
(blood ﬂow), the presence of immune inﬁltrate which
includeshighlyglucoseutilizingmacrophages[27],andareas
of hypoxia and consequent HIF-1 activation [28], all of
which will inﬂuence [18F]FDG. However, the purpose of
this paper was to determine the eﬀect of chemotherapy
agents on [18F]FDG incorporation by tumour cells in the
absence of other factors found in solid tumours. Our
ﬁndings indicate that, at least after 72 hours of treat-
ment, [18F]FDG incorporation is reduced during tumour
response to chemotherapy and tamoxifen treatment paral-
leling the ﬁndings of decreased [18F]FDG incorporation by
solid tumours responding to therapy reported in clinical
studies.
In conclusion, we have found that [18F]FDG incorpo-
ration by breast tumour cells in vitro is modulated by
chemotherapy in a time-dependent manner. ATP content
was decreased after 72 hours treatment with each agent
corresponding with decreased [18F]FDG incorporation at
this time point. Chemotherapy-induced changes in glucose
transport and hexokinase activity were not consistently
associated with decreased [18F]FDG incorporation.
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